FDA Deems Synapse’s Clinical Trials ‘Unacceptable’
EMA Recommended Suspension Of 400 Medicines Tested By The CRO Last December
Executive Summary
The FDA has followed the EMA’s lead and declared Synapse’s trials as “unacceptable.” Now, drug firms that used CRO’s services need to repeat their studies to regain therapeutic equivalence ratings.